Your browser doesn't support javascript.
loading
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon, Benjamin J; Tan, Lavinia; Lin, Jessica J; Wong, Stephen Q; Hollizeck, Sebastian; Ebata, Kevin; Tuch, Brian B; Yoda, Satoshi; Gainor, Justin F; Sequist, Lecia V; Oxnard, Geoffrey R; Gautschi, Oliver; Drilon, Alexander; Subbiah, Vivek; Khoo, Christine; Zhu, Edward Y; Nguyen, Michele; Henry, Dahlia; Condroski, Kevin R; Kolakowski, Gabrielle R; Gomez, Eliana; Ballard, Joshua; Metcalf, Andrew T; Blake, James F; Dawson, Sarah-Jane; Blosser, Wayne; Stancato, Louis F; Brandhuber, Barbara J; Andrews, Steve; Robinson, Bruce G; Rothenberg, S Michael.
Afiliación
  • Solomon BJ; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia. Electronic address: ben.solomon@petermac.org.
  • Tan L; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.
  • Lin JJ; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Wong SQ; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.
  • Hollizeck S; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.
  • Ebata K; Loxo Oncology, Inc., Stamford, Connecticut.
  • Tuch BB; Loxo Oncology, Inc., Stamford, Connecticut.
  • Yoda S; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Gainor JF; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Sequist LV; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
  • Oxnard GR; Dana Farber Cancer Institute, Boston, Massachusetts.
  • Gautschi O; Luzerner Kantonsspital, Luzern, Switzerland.
  • Drilon A; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Subbiah V; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Khoo C; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.
  • Zhu EY; Loxo Oncology, Inc., Stamford, Connecticut.
  • Nguyen M; Loxo Oncology, Inc., Stamford, Connecticut.
  • Henry D; Loxo Oncology, Inc., Stamford, Connecticut.
  • Condroski KR; Loxo Oncology, Inc., Stamford, Connecticut.
  • Kolakowski GR; Loxo Oncology, Inc., Stamford, Connecticut.
  • Gomez E; Loxo Oncology, Inc., Stamford, Connecticut.
  • Ballard J; Loxo Oncology, Inc., Stamford, Connecticut.
  • Metcalf AT; Loxo Oncology, Inc., Stamford, Connecticut.
  • Blake JF; Array BioPharma, Boulder, Colorado.
  • Dawson SJ; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.
  • Blosser W; Eli Lilly & Company, Indianapolis, Indiana.
  • Stancato LF; Eli Lilly & Company, Indianapolis, Indiana.
  • Brandhuber BJ; Loxo Oncology, Inc., Stamford, Connecticut.
  • Andrews S; Loxo Oncology, Inc., Stamford, Connecticut.
  • Robinson BG; Kolling Institute of Endocrinology, Royal North Shore Hospital, and the University of Sydney, Sydney, Australia.
  • Rothenberg SM; Loxo Oncology, Inc., Stamford, Connecticut.
J Thorac Oncol ; 15(4): 541-549, 2020 04.
Article en En | MEDLINE | ID: mdl-31988000
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas c-ret / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas c-ret / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article